Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2016 Publisher: Meda Pharmaceuticals Ltd, Skyway House, Parsonage Road, Takeley, Bishops Stortford, CM22 6PU, United Kingdom
Uraplex 20mg Coated Tablets.
Pharmaceutical Form |
---|
Coated tablet. Brownish-yellow, glossy coated, biconvex tablets. |
The active ingredient is trospium chloride. Each coated tablet contains 20 mg trospium chloride.
For a full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Trospium |
Trospium is an antispasmodic, antimuscarinic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Receptor assays showed that trospium has negligible affinity for nicotinic receptors as compared to muscarinic receptors at concentrations obtained from therapeutic doses. Trospium antagonizes the effect of acetylcholine on muscarinic receptors in cholinergically innervated organs. Its parasympatholytic action reduces the tonus of smooth muscle in the bladder. |
List of Excipients |
---|
Tablet core: Wheat starch Tablet coat: Sucrose Note for diabetics: one coated tablet corresponds to 0.06 g carbohydrate (equivalent to 0.005 bread units. |
PVC foiled aluminium blister.
Pack sizes approved: 2, 20, 28, 30, 40, 50, 56, 60, 90, 100, 120, 150, 200, 500, 600, 1000, 1200, 2000.
Not all pack sizes may be marketed.
Meda Pharmaceuticals Ltd, Skyway House, Parsonage Road, Takeley, Bishop’s Stortford, CM22 6PU, United Kingdom
PL 15142/0287
14/03/2011
Drug | Countries | |
---|---|---|
URAPLEX | Spain, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.